Programme & Trade Exhibition Guide 2012

4–7 November 2012
BT Convention Centre, Liverpool, UK
Contents

SUNDAY 4 NOVEMBER
Programme at a Glance 2

MONDAY 5 NOVEMBER
Programme at a Glance 3
Symposia 6
Parallel Sessions 8
Proffered Paper Sessions 11
Workshops 13

TUESDAY 6 NOVEMBER
Programme at a Glance 16
Symposia 19
Parallel Sessions 21
Proffered Paper Sessions 24
Workshops 26

WEDNESDAY 7 NOVEMBER
Programme at a Glance 30
Parallel Sessions 32
Programme at a Glance SUNDAY

Welcome Address
15.00 – 15.10  Introduction from the Chair of the NCRI
   Hall 1A  Professor Dame Janet Husband DBE, Chair of the National Cancer Research Institute, UK

Plenary Lectures
Chaired by Gerard Evan, University of Cambridge, UK
15.10 – 15.50  Metastasis seeds and niches
   Hall 1A  Joan Massagué, Memorial Sloan-Kettering Cancer Center, New York, USA
15.50 – 16.30  Signal transduction pathways and Hsp 90 inhibitors: Latest experiences and results from clinical trials (title TBC)
   Hall 1A  Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, USA

Refreshment Break
16.30 – 17.00  Refreshment break
Registration area & Galleria

Prize Awards
17.00 – 17.15  Cancer Research UK Prize ceremony
   Hall 1A  Presented by Harpal Kumar, Cancer Research UK, London, UK

Plenary Lecture
Chaired by Nic Jones, Chair of the Cancer Research UK Prizes Selection Panel
17.15 – 17.55  Cancer Research UK Lifetime Achievement in Cancer Research Prize winner
   Hall 1A  Drugging the undruggable: How to finally tackle Myc, Ras, and p53
   David Lane, Agency for Science, Technology and Research, Singapore

Opening Reception and Trade Exhibition
18.00 – 20.00  For further details, please refer to the Trade Exhibition section in this book
   Hall 2
Programme at a Glance MONDAY

Educational Workshop
08.00 – 08.45   BACR Educational Workshop
Room 11        Pre-clinical breast cancer models
Hosted by Valerie Speirs, Leeds Institute of Molecular Medicine, UK

Introduction to the Programme
08.50 – 09.00   Message from the Chair of the 2012 Programme Committee
Hall 1A         Patrick Johnston, Queen’s University Belfast, UK

Plenary Lectures
Chaired by Patrick Johnston, Queen’s University Belfast, UK
09.00 – 09.40   Targeting myeloma cells and their environment
Hall 1A         Kenneth C. Anderson, Jerome Lipper Myeloma Center, Dana-Farber
                Cancer Institute, Harvard Medical School, Boston, USA
09.40 – 10.20   Clinical cancer genetics in the era of personalised cancer medicine
Hall 1A         Judy E. Garber, Dana-Farber Cancer Institute, Boston, USA

Poster Session A (odd numbers), Refreshment Break and Trade Exhibition Viewing
10.20 – 11.00   For further details, please refer to the Poster Abstracts book or USB stick,
                and the Trade Exhibition section in this book
Hall 2

Symposia
11.00 – 12.30   Cancer in low and middle income countries - an increasing threat to
development
Room 3B
Hosted by Ian Magrath, International Network for Cancer
Treatment and Research (INCTR), Brussels, Belgium
11.00 – 12.30   Oncology drug development in 2012 - Challenges and opportunities
                of stratified patient populations
Room 11
Hosted by Susan Galbraith, AstraZeneca, Macclesfield, UK
11.00 – 12.30   Targeting cancer cells and promoting the immune effectors:
                From models to the clinic
Room 3A
Hosted by Adrian Hayday, King’s College London & Cancer
Research UK London Research Institute, UK
11.00 – 12.30   Understanding cancer as a microevolutionary process
Hall 1A        Hosted by Gerard Evan, University of Cambridge, UK

Lunch, Trade Exhibition Viewing and Poster Viewing
12.30 – 14.00   For further details, please refer to the Poster Abstracts book or USB stick,
                and the Trade Exhibition section in this book
Poster Session A (even numbers)
13.00 – 14.00  For further details, please refer to the Poster Abstracts book or USB stick
Hall 2

Proffered Paper Sessions
14.00 – 15.30  Diagnosis and therapy
Room 11  Hosted by Richard Adams, Velindre Cancer Centre, Cardiff, UK
14.00 – 15.30  Early diagnosis, care delivery and quality of life
Room 3A  Hosted by Peter Johnson, Cancer Research UK, London, UK
14.00 – 15.30  The cancer cell and model systems I
Hall 1A  Hosted by Owen Sansom, The Beatson Institute for Cancer Research, Glasgow, UK

Workshops
14.00 – 15.30  Does an appreciation of the arts make us more empathic communicators?
Room 4  Hosted by Lesley Fallowfield, SHORE-C, Brighton & Sussex Medical School, UK
14.00 – 15.30  Tailoring biobanks for stratified medicine - cutting your tissue to fit
Room 3B  Hosted by Daniel Glaser, Wellcome Trust, London, UK

Poster Session A (odd numbers “replay”), Refreshment Break and Trade Exhibition Viewing
15.30 – 15.50  For further details, please refer to the Poster Abstracts book or USB stick, and the Trade Exhibition section in this book
Hall 2

Parallel Sessions
15.50 – 17.20  Cachexia – relationship with cancer treatment toxicity and update on drug and non-drug approaches
Hall 1B  Hosted by Andrew Wilcock, The University of Nottingham, UK
15.50 – 17.20  Cancer inequalities in the UK
Room 3A  Hosted by Anna Gavin, Northern Ireland Cancer Registry, UK
15.50 – 17.20  Cold blooded cancer: Non-mammalian models for cancer research
Room 4  Hosted by Marcos Vidal, The Beatson Institute for Cancer Research, Glasgow, UK
15.50 – 17.20  Ovarian cancer: Turning knowledge into treatment
Room 3B  Hosted by Iain McNeish, Barts Cancer Institute, London, UK
15.50 – 17.20  Paediatric oncology (CCLG session)
Room 12  Hosted by Josef Vormoor on behalf of the Children’s Cancer & Leukaemia Group (CCLG), Northern Institute for Cancer Research, Newcastle University, UK
15.50 – 17.20  Predictive biomarker-driven phase II/III trials
Room 11  Hosted by Mahesh Parmar, Medical Research Council Clinical Trials Unit, London, UK
15.50 – 17.20  Rational approaches to combination of cancer therapies  
    Hall 1A  Hosted by Ultan McDermott, Wellcome Trust Sanger Institute, Cambridge, UK
15.50 – 17.20  Surgery in the era of biomarkers and novel systematic and regional therapies  
    Hall 1C  Hosted by Malcolm Dunlop, University of Edinburgh & Western General Hospital, UK

Refreshment Break  
17.20 – 17.40  Refreshment break  
    Hall 2

Plenary Lecture  
Chaired by Irene Higginson, Cicely Saunders Institute, King’s College London, UK  
17.40 – 18.20  Cancer pain control  
    Hall 1A  Eduardo Bruera, The University of Texas MD Anderson Cancer Center, USA

Plenary Lecture  
Chaired by Chris Boshoff, University College London Cancer Institute, UK  
18.20 – 19.00  Targeting the CRKL/Src family kinases in rhabdomyosarcoma  
    Hall 1A  Lee J. Helman, National Cancer Institute, Bethesda, USA

Drinks Reception and Trade Exhibition viewing  
19.00 – 21.15  For further details, please refer to the Trade Exhibition section in this book  
    Hall 2

Chair’s Reception (by invitation)  
20.00 – 22.30  Grace Suite, The Hilton Liverpool
## Cancer in low and middle income countries - an increasing threat to development

**Room 3B**  
**Hosted by Ian Magrath,** International Network for Cancer Treatment and Research (INCTR), Brussels, Belgium

11.00 – 11.15  
**Introduction**  
Ian Magrath, International Network for Cancer Treatment and Research (INCTR), Brussels, Belgium

11.15 – 11.40  
**Descriptive epidemiology of cancer in developing countries and its importance to cancer control**  
D. Maxwell Parkin, Clinical Trial Service Unit, University of Oxford & Cancer Registry Programme, International Network for Cancer Treatment and Research, Oxford, UK

11.40 – 12.05  
**Recent advances in breast, cervix and oral cancer: Early detection and prevention in low and middle income countries**  
Rengaswamy Sankaranarayanan, International Agency for Research on Cancer, World Health Organisation, Lyon, France

12.05 – 12.30  
**Cancer control for India and the developing world**  
Rajendra Badwe, Tata Memorial Centre, Mumbai, India

---

## Oncology drug development in 2012 - Challenges and opportunities of stratified patient populations

**Room 11**  
**Hosted by Susan Galbraith,** AstraZeneca, Macclesfield, UK

11.00 – 11.15  
**Introduction**  
Susan Galbraith, AstraZeneca, Macclesfield, UK

11.15 – 11.40  
**Translating pre-clinical hypotheses into the clinic – A tale of two kinases**  
Nigel Brooks, AstraZeneca, Macclesfield, UK

11.40 – 12.05  
**Developing novel anti-cancer therapies: Promises and challenges**  
Jeff Evans, The Beatson Institute for Cancer Research, University of Glasgow & NHS Greater Glasgow and Clyde, Glasgow, UK

12.05 – 12.30  
**Delivering on the promise of personalised medicine**  
Gordon Mills, The University of Texas MD Anderson Cancer Center, Texas, USA

---

## Targeting cancer cells and promoting the immune effectors: From models to the clinic

**Room 3A**  
**Hosted by Adrian Hayday,** King’s College London & Cancer Research UK London Research Institute, UK

11.00 – 11.15  
**Introduction**  
Adrian Hayday, King’s College London & Cancer Research UK London Research Institute, UK

11.15 – 11.40  
**Live imaging of the earliest inflammatory response to transformed cells within tissues - studies in zebrafish**  
Paul Martin, University of Bristol, UK

11.40 – 12.05  
**Peptide antigen characterisation for clinical immunotherapy studies**  
Hans-Georg Rammensee, University of Tübingen, Germany

12.05 – 12.30  
**PD-1 and LAG-3 in cancer immunotherapy**  
Charles G. Drake, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00 – 11.15</td>
<td><strong>Introduction</strong>&lt;br&gt;Gerard Evan, University of Cambridge, UK</td>
</tr>
<tr>
<td>11.15 – 11.40</td>
<td><strong>Recent insights into the tempo and mode of somatic evolution</strong>&lt;br&gt;Carlo Maley, The University of California, San Francisco, USA</td>
</tr>
<tr>
<td>11.40 – 12.05</td>
<td><strong>Evolutionary complexity in childhood acute lymphoblastic leukaemia</strong>&lt;br&gt;Mel Greaves, The Institute of Cancer Research, London, UK</td>
</tr>
<tr>
<td>12.05 – 12.30</td>
<td><strong>Evolution of cancer genomes</strong>&lt;br&gt;Peter Campbell, Wellcome Trust Sanger Institute, Cambridge, UK</td>
</tr>
</tbody>
</table>
Parallel Sessions MONDAY

Cachexia – relationship with cancer treatment toxicity and update on drug and non-drug approaches

Hall 1B  Hosted by Andrew Wilcock, The University of Nottingham, UK
15.50 – 16.05  Introduction
Andrew Wilcock, The University of Nottingham, UK
16.05 – 16.30  Role of cachexia in cancer treatment toxicity
Michael Sawyer, University of Alberta, Edmonton, Canada
16.30 – 16.55  Cancer cachexia: The molecular mechanisms
Josep M. Argilés, University of Barcelona, Spain
16.55 – 17.20  The role of therapeutic exercise in cancer cachexia
Matthew Maddocks, Cicely Saunders Institute, King’s College London, UK

Cancer inequalities in the UK

Room 3A  Hosted by Anna Gavin, Northern Ireland Cancer Registry, UK
15.50 – 16.05  Introduction
Anna Gavin, Northern Ireland Cancer Registry, UK
16.05 – 16.30  Cancer inequalities and inequities in older people in the UK
Tony Moran, North West Cancer Intelligence Service & The Christie NHS Foundation Trust, Manchester, UK
16.30 – 16.55  Inequalities in cancer outcomes
Michel Coleman, London School of Hygiene and Tropical Medicine, UK
16.55 – 17.20  Cancer inequalities - a perspective from England
Sir Mike Richards, National Cancer Director, National Cancer Action Team, London, UK

Cold blooded cancer: Non-mammalian models for cancer research

Room 4  Hosted by Marcos Vidal, The Beatson Institute for Cancer Research, Glasgow, UK
15.50 – 16.05  Introduction
Marcos Vidal, The Beatson Institute for Cancer Research, Glasgow, UK
16.05 – 16.30  Anchor cell invasion in C. elegans - Cell cycle progression antagonises invasion
David Sherwood, Duke University, Durham, USA
16.30 – 16.55  Intestinal stem cell control in the healthy and hyperplastic Drosophila gut
Bruce Edgar, DKFZ-ZMBH Alliance, Heidelberg, Germany
16.55 – 17.20  Novel determinants of melanoma progression from zebrafish
Adam Hurlstone, The University of Manchester, UK
Ovarian cancer: Turning knowledge into treatment

Room 3B
Hosted by Iain McNeish, Barts Cancer Institute, London, UK

15.50 – 16.05 Introduction
Iain McNeish, Barts Cancer Institute, London, UK

16.05 – 16.30 Ovarian cancer screening - the future
Usha Menon, University College London, UK

16.30 – 16.55 Genomics and the personalisation of ovarian cancer care
David Huntsman, BC Cancer Agency, Vancouver, Canada

16.55 – 17.20 Clinical implications of intratumoural heterogeneity on high-grade serous ovarian cancer
James Brenton, Cancer Research UK Cambridge Research Institute, UK

Paediatric oncology (CCLG session)

Room 12
Hosted by Josef Vormoor on behalf of the Children’s Cancer & Leukaemia Group (CCLG), Northern Institute for Cancer Research, Newcastle University, UK

15.50 – 16.05 Winner of the 2012 CCLG McElwain Prize: Dissecting the clonal architecture of paediatric leukaemia
Nicola Potter, The Institute of Cancer Research, London, UK

16.05 – 16.30 Distinct biological drivers of high grade glioma in children and young adults
Lynn Bjerke, The Institute of Cancer Research, London, UK

16.30 – 16.55 Immunotherapeutic approaches in childhood high grade glioma
John Anderson, University College London & Institute of Child Health, Great Ormond Street Hospital, UK

16.55 – 17.20 Challenges of introducing biologically targeted therapy in paediatric high grade glioma
Darren Hargrave, Great Ormond Street Hospital, London, UK

Predictive biomarker-driven phase II/III trials

Room 11
Hosted by Mahesh Parmar, Medical Research Council Clinical Trials Unit, London, UK

15.50 – 16.05 Introduction
Mahesh Parmar, Medical Research Council Clinical Trials Unit, London, UK

16.05 – 16.30 The development and validation of predictive biomarkers for phase II/III studies
Richard Kennedy, Queen’s University Belfast, UK

16.30 – 16.55 Predictive biomarker trials in breast cancer
Jo Anne Zujewski, National Cancer Institute, Bethesda, USA

16.55 – 17.20 The design of FOCUS 4: A molecularly-stratified, multi-arm multistaged (MAMS) randomised controlled trial phase II/III programme in advanced colorectal cancer (ACRC)
Timothy Maughan, University of Oxford, UK

Rational approaches to combination of cancer therapies

Hall 1A
Hosted by Ultan McDermott, Wellcome Trust Sanger Institute, Cambridge, UK

15.50 – 16.05 Introduction
Ultan McDermott, Wellcome Trust Sanger Institute, Cambridge, UK

16.05 – 16.30 Targeting unique dependencies of RAS mutant tumours by combined pathway inhibition
Julian Downward, Cancer Research UK London Research Institute, UK
16.30 – 16.55  The application of genetic screens and principles to the design of drug combination strategies  
Christopher Lord, The Institute of Cancer Research, London, UK

16.55 – 17.20  Complex molecular interactions as determinants of disease outcome and therapy response  
Lodewyk Wessels, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Surgery in the era of biomarkers and novel systematic and regional therapies

Hall 1C  Hosted by Malcolm Dunlop, University of Edinburgh & Western General Hospital, UK

15.50 – 16.05  Introduction  
Malcolm Dunlop, University of Edinburgh & Western General Hospital, UK

16.05 – 16.30  The implications of clonal genome evolution for cancer medicine  
Sam Aparicio, BC Cancer Agency Research Centre, Vancouver, Canada

16.30 – 16.55  The search for biomarkers in prostate cancer  
Freddie Hamdy, University of Oxford, UK

16.55 – 17.20  Pancreas cancer genetics and the surgeon - should you care?  
Steven Gallinger, University of Toronto, Canada
Diagnosis and therapy

**Room 11**  
*Hosted by Richard Adams*, Velindre Cancer Centre, Cardiff, UK

**14.00 – 14.10**  
Seven year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer  
*Ben Green*, University of Leeds, UK

**14.10 – 14.20**  
EPOC Trial: EORTC liver metastases intergroup randomised phase III study 40983 - Long-term survival results  
*John Primrose*, University of Southampton, UK

**14.20 – 14.30**  
HiLo: Multicentre randomised phase III clinical trial of high vs. low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation for differentiated thyroid cancer (DTC)  
*Allan Hackshaw*, University College London, UK

**14.30 – 14.40**  
Results of KRAS/BRAF/NRAS all-wild-type outcome analysis in the MRC COIN-B randomised trial in patients with advanced colorectal cancer  
*Harpreet Wasan*, Imperial College Healthcare NHS Trust, London, UK

**14.40 – 14.50**  
Identification of reprogramming of the kinome following vemurafenib treatment in *BRAF* mutant colorectal cancer cells  
*Robbie Carson*, Queen’s University Belfast, UK

**14.50 – 15.00**  
Tyrosine phosphatase inhibitors combine with retinoic acid to enhance neuroblastoma cell differentiation and trigger ERK- and AKT-dependent, p53-independent senescence  
*Andrew Stoker*, Institute of Child Health, University College London, UK

**15.00 – 15.10**  
Identification of 23 novel prostate cancer susceptibility loci using a custom array (the iCOGS) in an international consortium, PRACTICAL  
*Chee Goh*, The Institute of Cancer Research, London, UK

**15.10 – 15.20**  
Performance characteristics of multimodal screening with serum CA125 in the United Kingdom collaborative trial of ovarian cancer screening (UKCTOCS)  
*Ian Jacobs*, University College London Elizabeth Garrett Anderson Institute for Women’s Health, London & The University of Manchester, UK

**15.20 – 15.30**  
Discussion

---

Early diagnosis, care delivery and quality of life

**Room 3A**  
*Hosted by Peter Johnson*, Cancer Research UK, London, UK

**14.00 – 14.10**  
Epidemiology and molecular pathology of the first 1000 participants in the Cancer Research UK Stratified Medicine Programme  
*Emily Shaw*, Cancer Research UK, London, UK

**14.10 – 14.20**  
Breast cancer diagnosis and treatment in women aged 18-40 years in the UK: Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH)  
*Bryony Eccles*, University of Southampton, UK
14.20 – 14.30 Identification of men with a genetic predisposition to prostate cancer - Targeted screening of BRCA1/2 mutation carriers and controls: The IMPACT study
Elizabeth Page, The Institute of Cancer Research, London, UK

14.30 – 14.40 Community cancer treatment: Final results of the Outreach randomised clinical trial
Pippa Corrie, Addenbrooke’s Hospital, Cambridge, UK

Fiona Mendes, North Wales Centre for Primary Care Research, North Wales Clinical School, Wrexham, UK

14.50 -15.00 A comparison of clinician- versus patient-reported outcomes (PROMS) for late normal tissue side-effects following breast radiotherapy: Results of the Cambridge Breast Intensity Modulated Radiotherapy Trial (IMRT) Trial
Charleen Chan Wah Hak, University of Cambridge, UK

15.00 – 15.10 Measuring quality of life for QALY estimation with cyclical cancer therapies
Felicity Roussak, University of Leeds, UK

15.10 – 15.20 Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up
Suneil Jain, Sunnybrook Odette Cancer Centre, Toronto, Canada

15.20 – 15.30 Discussion

The cancer cell and model systems I

Hall 1A Hosted by Owen Sansom, The Beatson Institute for Cancer Research, Glasgow, UK

14.00 – 14.15 AstraZeneca Student Prize Award: Identification of metabolic genes essential for proliferation of clear cell renal cell carcinoma (ccRCC) cells
Heike Miess, Cancer Research UK London Research Institute, UK

14.15 – 14.30 ACP McElwain Prize: The preclinical and clinical development of AKT inhibitors and associated biomarkers
Timothy A. Yap, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK

14.30 – 14.40 Association of ALKF1174L expression with altered vasculature in transgenic murine models of neuroblastoma
Laura Glass, The Institute of Cancer Research, London, UK

14.40 – 14.50 Propagation of epithelial polarity through mitosis
Graham Bell, Cancer Research UK & University College London, UK

14.50 – 15.00 The c-MET-JAK1/2-STAT3 signalling axis is a critical mediator of drug resistance in Kras mutant colorectal cancer
Sandra Van Schaeybroeck, Queen’s University Belfast, UK

15.00 – 15.10 Colorectal tumour microRNAs - novel biomarkers of tumour progression and treatment response?
Edward Amankwatia, University of Dundee, UK

15.10 – 15.20 Inhibition of Ras-dependent cellular transformation and tumourigenesis by transcription factor, ATF2
Malgorzata Grozdecka, Paterson Institute for Cancer Research, Manchester, UK

15.20 – 15.30 Discussion
BACR Educational Workshop

Pre-clinical breast cancer models

Hosted by Valerie Speirs, Leeds Institute of Molecular Medicine, UK

08.00 – 08.45, Room 11

Breast cancer is a complex and heterogeneous disease. Such heterogeneity has been recognised further with breast cancer now classified into at least 10 molecular subtypes. In addition, the recognition that the breast microenvironment plays an active role in dictating mammary epithelial cell behaviour calls for a need for models which better define the in vivo environment to use in breast cancer research. Given that breast cancer is so diverse one single model is unlikely to recapitulate all aspects of breast cancer progression. This workshop will outline the pros and cons of different types of breast cancer models, from simple 2D to more complex 3D in vitro models, through to animal models to study metastasis. Their suitability to address different biological questions will be discussed.


Speakers:

Breast cancer metastasis - how do we choose the right in vivo model?

Ingunn Holen, University of Sheffield, UK

In vivo models remain a key part of the cancer researcher’s toolkit, generating valuable data that provide new insights into mechanisms of cancer progression and response to therapy. The models are particularly valuable for studies of metastatic disease, a complex process that cannot be adequately mimicked in vitro. Increasingly, researchers find that some evidence of function or efficacy from in vivo models is required in order to publish their findings in high impact journals. Choosing the right model(s) to answer a specific research question is of great importance, and requires a clear understanding of the strengths and limitations of a particular model. Some models are suited to studies of the early stages of tumour growth and initiation of metastasis, others to investigate growth in particular organ sites. No single model will be a perfect representation of human tumour metastasis, and careful interpretation of the resulting data is essential. With emphasis on bone metastasis, I will show some examples of novel insights into breast cancer obtained from in vivo models, and highlight the strengths and weaknesses of the approach.

3D in vitro model systems of breast cancer: Where are we now and where are we going?

J. Louise Jones, Barts Cancer Institute, London, UK

A major challenge for any in vitro model system is to achieve physiological relevance. In this respect, moving from the traditional 2D monolayer cell culture system to the 3D environment has been a significant advance, allowing the roles of dimensionality, extracellular matrix and cell-cell interactions to be taken into account. Some of the first 3D systems were described by the labs of Brugge and Bissell, who used overlay of breast epithelial cells with reconstituted basement membrane to generate a 3D culture, and showed that moving from 2D to 3D alone influences cell differentiation, growth kinetics and metabolic rate. Since these groundbreaking studies, systems of greater complexity have been developed that have allowed modelling of the interactions between different cell populations, different matrices and mechanical forces. These models typically involve formation of a matrix ‘gel’ within which the cells are embedded, either as single cells or as preformed multicellular units. The advantage of such systems is the relative complexity that begins to mirror the in vivo environment, but challenges include variability between cultures, the large number of cells required and limitations in quantification. Some of these limitations can be addressed using organotypic culture systems, such as improved quantitation of processes such as invasion, but reproducibility remains an issue.
An engineered poly(dimethylsiloxane) (PDMS) microwell array system has been developed for the standardised screening of tumour response to drug treatments. This system allows culture of cells in a 3D environment where both control of cell cluster size and protein coating can be controlled independently. This system has the advantage of high reproducibility, but arguably at the expense of complexity.

A further disadvantage of conventional 3D model systems is that they are labour intensive and require large numbers of cells. Microfluidic approaches offer opportunities for significant scalability and automation, with real potential for high-throughput screening. These systems have recently been applied to multicellular co-culture models of DCIS, so combining complexity with efficiency, and mark an exciting development in the field of bioengineering.


### Afternoon Workshops

**Does an appreciation of the arts make us more empathic communicators?**

**Hosted by Lesley Fallowfield,** SHORE-C, Brighton & Sussex Medical School, UK

14.00 – 15.30, Room 4

Emotional burnout in oncologists is high. Many seek solace in ways unlikely to improve psychological well-being and that damage relationships with patients and professional colleagues.

This session should increase awareness of the role of the arts in helping patients, carers and healthcare professionals articulate the powerful emotions experienced in an oncology setting.

**White coat and purple coat: The writings and influence of Dr Dannie Abse (poet, playwright and physician)**

**Irene Higginson,** Cicely Saunders Institute, King’s College London, UK

‘The Emotional Cancer Journey’

DVD of the paintings and writings of Michele Angelo Petrone, an Italian painter who died of Hodgkin’s Disease. The background music (Spiegel Im Spiegel by Arvo Part) is played by Tamsin Little, the voice of Michele Petrone - William Gaminara

**Tailoring biobanks for stratified medicine - cutting your tissue to fit**

**Hosted by Daniel Glaser,** Wellcome Trust, London, UK

14.00 – 15.30, Room 3B

Science never stands still. One of the challenges of tissue banking for research is to future proof our resources. Tissue Bankers need to keep abreast of new technologies and new guidelines for reporting scientific studies to ensure that the material that they collect from patients now is useful for science in the future. This workshop looks at three key areas — ensuring that samples come with sufficient annotation and quality standards for results obtained from them to be published in the most highly rated journals; how collection strategies can be developed to ensure that we have the right samples from patients to answer relevant clinical questions in the future; and how new technologies and animal models for research using clinical material have great potential in directing treatment strategies for both the patients of today and tomorrow.

The workshop is chaired by Daniel Glaser, who is Head of Special Projects for Public Engagement at the Wellcome Trust. Following talks by our three speakers, there will be a discussion on the issues raised. Come and help us provide you with what you need for your future research.

**Alison Parry-Jones, Wales Cancer Bank, Cardiff, UK**
Speakers:

Quality of science on human material – is it improving?
Doug Altman, University of Oxford, UK

Metastatic biobanking
Noel Clarke, The University of Manchester, UK

Human tissue in animal models
Speaker TBC
Programme at a Glance TUESDAY

Educational Workshop
08.00 – 08.45  BACR Educational Workshop
Room 11  Translation of radiation biology into meaningful clinical trials: All aboard!
  Hosted by Ricky Sharma, University of Oxford, UK

Plenary Lectures
Chaired by Jane Barrett, President of The Royal College of Radiologists, UK
09.00 – 09.25  The breast screening review
Hall 1A  Harpal Kumar, Cancer Research UK, London, UK
09.25 – 09.50  The breast screening review: Evidence and recommendations
Hall 1A  Sir Michael Marmot, Institute of Health Equity, University College London, UK
09.50 – 10.20  Q&A session

Poster Session B (odd numbers), Refreshment Break and Trade Exhibition Viewing
10.20 – 11.00  For further details, please refer to the Poster Abstracts book or USB stick, and the Trade Exhibition section in this book

Educational Workshop
11.00 – 15.00  Cutting edge translational research in head and neck cancer
Room 4  Hosted by Hisham Mehanna, Institute of Head and Neck Studies and Education, Coventry, UK

Symposia
11.00 – 12.30  Improvements in palliative and supportive care: Recent advances
Room 3A  Hosted by Irene Higginson, Cicely Saunders Institute, King’s College London, UK
11.00 – 12.30  Lung cancer - state of the art and science
Room 3B  Hosted by Fergus Macbeth, Wales Cancer Trials Unit, Cardiff, UK
11.00 – 12.30  Tumour-environment interactions
Hall 1A  Hosted by Margaret Frame, Edinburgh Cancer Research Centre, UK
11.00 – 12.30  Where next with genome-wide association studies?
Room 11  Hosted by Bruce Ponder, Cancer Research UK Cambridge Research Institute, UK

Lunch, Trade Exhibition Viewing and Poster Viewing
12.30 – 14.00  For further details, please refer to the Poster Abstracts book or USB stick, and the Trade Exhibition section in this book
Programme at a Glance

TUESDAY 6

Commercial Workshop
13.00 – 14.00  Headlines of International Conferences in 2012
Room 11  Sponsored by Roche Products Limited

Poster Session B (even numbers)
13.00 – 14.00  For further details, please refer to the Poster Abstracts book or USB stick,
Hall 2  and the Trade Exhibition section in this book

Proffered Paper Sessions
14.00 – 15.30  Cancer awareness, early diagnosis and care
Room 3A  Hosted by Richard Neal, Bangor University, UK
14.00 – 15.30  Radiotherapy and radiobiology
Room 11  Hosted by Adrian Crellin, St. James’s Institute of Oncology, Leeds,
UK & Vice Preseident, The Royal College of Radiologists, UK
14.00 – 15.30  The cancer cell and model systems II
Hall 1A  Hosted by Caroline Dive, Paterson Institute for Cancer Research,
Manchester, UK

Workshops
14.00 – 15.30  Improving the management of cerebral metastatic disease
Room 12  Hosted by NCRI Brain Tumour Clinical Studies Group, UK
14.00 – 15.30  Transforming oncology research: New models for novel
Room 3B  therapeutic approaches
Hosted by French National Cancer Institute (INCa), France

Parallel Sessions
15.50 – 17.20  Cell death, necroptosis and beyond
Room 4  Hosted by Henning Walczak, Imperial College London, UK
15.50 – 17.20  Human factors in early diagnosis
Hall 1C  Hosted by Jane Wardle, University College London, UK
15.50 – 17.20 Mechanisms of drug resistance
   Hall 1A Hosted by Julian Downward, Cancer Research UK London Research Institute, UK
15.50 – 17.20 Patients, participants and public – Different perspectives, shared views?
   Room 12 Hosted by Richard Stephens, NCRI Consumer Liaison Group, UK
15.50 – 17.20 Primary and secondary cancer prevention – lifestyle interventions
   Room 3B Hosted by Annie Anderson, University of Dundee, UK
15.50 – 17.20 Stem cells, heterogeneity and clonal evolution in cancer
   Room 11 Hosted by Tariq Enver, University College London Cancer Institute, UK

Refreshment Break
17.20 – 17.40 Refreshment break
   Hall 2

Clinical Trials Showcase
   Chaired by Matt Seymour, National Cancer Research Network, Leeds, UK
17.40 – 18.00 Final analysis of intergroup randomised phase III study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110)
   Hall 1A Malcolm Mason, Cardiff University, UK
18.00 – 18.20 The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial
   Hall 1A David Sebag-Montefiore, St James’s Institute of Oncology, University of Leeds, UK
18.20 – 18.40 Treatment of advanced neuroendocrine tumours: Final results of the UKI NETS and NCRI randomised phase 2 NET 01 trial
   Hall 1A Pippa Corrie, Addenbrooke’s Hospital, Cambridge, UK
18.40 – 19.00 Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in oesophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib)
   Hall 1A David R. Ferry, Russells Hall Hospital, Dudley, UK

Quality in Care Oncology Programme Awards (by invitation)
19.30 – 22.00 Grace Suite, The Hilton Liverpool

Conference dinner and party (ticketed event)
20.00 onwards The Marquee, BT Convention Centre
Symposia TUESDAY

Improvements in palliative and supportive care
Room 3A Hosted by Irene Higginson, Cicely Saunders Institute, King’s College London, UK

11.00 – 11.15 Introduction
Irene Higginson, Cicely Saunders Institute, King’s College London, UK

11.15 – 11.40 Advances, challenges and opportunities in symptom management in older patients with cancer
Deborah Dudgeon, Queen’s University, Ontario, Canada

11.40 – 12.05 Recent advances in developing a national end-of-life care register
Carl Johan Fürst, Karolinska Institutet & Stockholms Sjukhem Foundation, Stockholm, Sweden

12.05 – 12.30 Recent advances in the detection and management of psychological distress and depression in cancer and palliative care
Mari Lloyd-Williams, University of Liverpool, UK

Lung cancer - state of the art and science
Room 3B Hosted by Fergus Macbeth, Wales Cancer Trials Unit, Cardiff, UK

11.00 – 11.15 Introduction
Fergus Macbeth, Wales Cancer Trials Unit, Cardiff, UK

Frances Shepherd, University of Toronto and Princess Margaret Hospital, Ontario, Canada

11.40 – 12.05 Lung Sterotactic Ablative Radiotherapy (SABR): The state of the art
Kevin Franks, St James’s Institute of Oncology, Leeds, UK

12.05 – 12.30 Radical radiotherapy for locally advanced NSCLC - Current research and controversies
Corinne Faivre-Finn, The Christie NHS Foundation Trust, Manchester, UK

Tumour-environment interactions
Hall 1A Hosted by Margaret Frame, Edinburgh Cancer Research Centre, UK

11.00 – 11.15 Introduction
Margaret Frame, Edinburgh Cancer Research Centre, UK

11.15 – 11.40 Tumour:stroma interactions in breast cancer metastasis
Clare Isacke, The Institute of Cancer Research, London, UK

11.40 – 12.05 Prognostic, predictive and therapeutic potential of PDGFR - positive cancer-associated fibroblasts
Arne Östman, Karolinska Institutet, Stockholm, Sweden

12.05 – 12.30 Intravital microscopy of tumour cells and their microenvironment through imaging windows
Jacco van Rheenen, Hubrecht Institute, Utrecht, The Netherlands
# Where next with genome-wide association studies?

**Room 11**

**Hosted by Bruce Ponder,** Cancer Research UK Cambridge Research Institute, UK

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00 – 11.15</td>
<td><strong>Introduction</strong>&lt;br&gt;<strong>Bruce Ponder,</strong> Cancer Research UK Cambridge Research Institute, UK</td>
</tr>
<tr>
<td>11.15 – 11.40</td>
<td><strong>Polygenic risk prediction: The clinical significance</strong>&lt;br&gt;<strong>Paul Pharoah,</strong> University of Cambridge, UK</td>
</tr>
<tr>
<td>11.40 – 12.05</td>
<td><strong>Unexplained familial breast cancer risk - how can we find the missing genes?</strong>&lt;br&gt;<strong>Julian Peto,</strong> London School of Hygiene and Tropical Medicine, UK</td>
</tr>
<tr>
<td>12.05 – 12.30</td>
<td><strong>Interrogating regulatory networks to elucidate drivers of tumourigenesis, progression, and drug sensitivity</strong>&lt;br&gt;<strong>Andrea Califano,</strong> Columbia University, New York, USA</td>
</tr>
</tbody>
</table>
Parallel Sessions TUESDAY

KEY TO THEMES:
- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

Acute oncology

Room 3A  Hosted by Diana Tait, The Royal College of Radiologists, UK
15.50 – 16.10  The impact of acute oncology services on the management of malignant spinal cord compression (MSCC) in the UK: Early results of the Royal College of Radiologists’ re-audit
Imogen Locke, The Royal Marsden NHS Foundation Trust, London, UK

16.10 – 16.30  Unknown primary team, pathways and outcomes
Gillian Knowles, NHS Lothian, Edinburgh, UK

16.30 – 16.50  Development of an oncology assessment area at the Edinburgh Cancer Centre
Fiona Nussey, NHS Lothian, Edinburgh, UK

16.50 – 17.10  Acute oncology - Models of delivery
Brian Haylock, Clatterbridge Cancer Centre, Wirral, UK

17.10 – 17.20  COAST-II: Development of a programme for equivalence assessment in IMRT treatment planning
Rajesh Jena, Cambridge University Hospitals NHS Foundation Trust, UK

Advances in the biology and treatment of liver malignancy

Hall 1B  Hosted by John Primrose, University of Southampton & Southampton General Hospital, UK
15.50 – 16.05  Introduction
John Primrose, University of Southampton & Southampton General Hospital, UK

16.05 – 16.30  Management of hepatocellular carcinoma
Jean-François Dufour, University of Berne, Switzerland

16.30 – 16.55  Biliary tract cancer: Progress and challenges
John Bridgewater, University College London Cancer Institute, UK

16.55 – 17.20  Colorectal liver metastases
John Primrose, University of Southampton & Southampton General Hospital, UK

Cell death, necroptosis and beyond

Room 4  Hosted by Henning Walczak, Imperial College London, UK
15.50 – 16.05  Introduction
Henning Walczak, Imperial College London, UK
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16.05 – 16.30| Role of RIPK1 and RIPK3 in cell death modality switches<br>
Peter Vandenabeele, Flanders Institute for Biotechnology (VIB) & Ghent University (UGent), Belgium |
| 16.30 – 16.55| IAPs: From caspase inhibitors to modulators of NF-κB, inflammation and cancer<br>
Pascal Meier, The Institute of Cancer Research, London, UK |
| 16.55 – 17.20| Cutting both ways: How caspases promote and prevent cell death<br>
Douglas Green, St. Jude Children’s Research Hospital, Memphis, USA |

**Human factors in early diagnosis**

- **Hall 1C** Hosted by Jane Wardle, University College London, UK
  - 15.50 – 16.05 Introduction<br>
    Jane Wardle, University College London, UK
  - 16.05 – 16.30 Public knowledge and attitudes towards early diagnosis<br>
    Jane Wardle, University College London, UK
  - 16.30 – 16.55 Increasing early detection of symptomatic lung cancer - results of a combined marketing communications campaign and primary care education programme in Leeds, UK<br>
    Matthew Callister, St. James’s University Hospital, Leeds, UK
  - 16.55 – 17.20 The use and misuse of numeric information about health risks<br>
    Mirta Galesic, Max Planck Institute for Human Development, Berlin, Germany

**Mechanisms of drug resistance**

- **Hall 1A** Hosted by Julian Downward, Cancer Research UK London Research Institute, UK
  - 15.50 – 16.05 Introduction<br>
    Julian Downward, Cancer Research UK London Research Institute, UK
  - 16.05 – 16.30 Challenges in overcoming resistance to targeted therapies<br>
    Jeffrey Engelman, Massachusetts General Hospital, USA
  - 16.30 – 16.55 Resistance to PARP inhibition in mouse models of BRCA1-deficient breast cancer<br>
    Sven Rottenberg, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  - 16.55 – 17.20 Mechanisms of estrogen receptor transcription in breast cancer<br>
    Jason Carroll, Cancer Research UK Cambridge Research Institute, UK

**Patients, participants and public – Different perspectives, shared views?**

- **Room 12** Hosted by Richard Stephens, NCRI Consumer Liaison Group, UK
  - 15.50 – 15.55 Introduction<br>
    Richard Stephens, NCRI Consumer Liaison Group, UK
  - 15.55 – 16.15 Cancer research - a positive response from patients<br>
    Carolyn Morris, NCRI Consumer Liaison Group, UK
  - 16.15 – 16.35 The National Cancer Patient Experience Survey<br>
    Reg Race, Quality Health, UK
  - 16.35 – 16.55 From RAGs to riches - Taking public and patient involvement from the high street to the bedside<br>
    Ian Lewis, Tenovus, Cardiff, UK
  - 16.55 – 17.15 Q&A
  - 17.15 – 17.20 Summary
Primary and secondary cancer prevention – lifestyle interventions

Room 3B
Hosted by Annie Anderson, University of Dundee, UK

15.50 – 16.05 Introduction
Annie Anderson, University of Dundee, UK

16.05 – 16.30 Weight management in breast cancer - a primary prevention challenge?
Michelle Harvie, Genesis Prevention Centre, University Hospital South Manchester, UK

16.30 – 16.55 Lifestyle change in cancer survivors...do we wait for trial evidence?
Wendy Demark-Wahnefried, University of Alabama at Birmingham, USA

16.55 – 17.20 The importance of physical activity for cancer survivors: Current evidence and ongoing research
Johannes Brug, VU University Medical Centre, Amsterdam, The Netherlands

Stem cells, heterogeneity and clonal evolution in cancer

Room 11
Hosted by Tariq Enver, University College London Cancer Institute, UK

15.50 – 16.05 Introduction
Tariq Enver, University College London Cancer Institute, UK

16.05 – 16.30 Mechanisms regulating cutaneous cancer stem cells
Cedric Blanpain, Université Libre de Bruxelles & IRIBHM-WELBIO, Brussels, Belgium

16.30 – 16.55 Cancer stem cells from human brain tumours
Peter Dirks, The Hospital for Sick Children, Toronto, Canada

16.55 – 17.20 Clonal evolution and intratumour heterogeneity
Charlie Swanton, University College London Cancer Institute, UK
### Cancer awareness, early diagnosis and care

**Room 3A** Hosted by Richard Neal, Bangor University, UK

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.10</td>
<td>Population based testing for inherited cancer predisposing BRCA1/2 mutations is acceptable and detects at risk carriers without a strong family history of cancer</td>
<td>Ian Jacobs, The University of Manchester &amp; University College London Elizabeth Garrett Anderson Institute for Women’s Health, UK</td>
</tr>
<tr>
<td>14.10 – 14.20</td>
<td>Perceptions of the English NHS Bowel Cancer Screening Programme information materials: A Think-Aloud Study</td>
<td>Samuel G. Smith, University College London, UK</td>
</tr>
<tr>
<td>14.20 – 14.30</td>
<td>The association between the number of general practitioner consultations before hospital referral for cancer and primary care interval (‘delay’): Data from the English National Audit of Cancer Diagnosis in Primary Care</td>
<td>Georgios Lyratzopoulos, University of Cambridge, UK</td>
</tr>
<tr>
<td>14.50 – 15.00</td>
<td>Experience of breathlessness and pain by post surgical lung cancer survivors during the first post operative year: A qualitative study</td>
<td>Amanda Farley, University of Birmingham, UK</td>
</tr>
<tr>
<td>15.00 – 15.10</td>
<td>Factors associated with low health-related quality-of-life in colorectal cancer survivors: The importance of family, socio-economic and financial circumstances</td>
<td>Linda Sharp, National Cancer Registry Ireland, UK</td>
</tr>
<tr>
<td>15.10 – 15.20</td>
<td>Change in commonly recorded clinical parameters in the final two weeks of life</td>
<td>Paul Taylor, Hull and York Medical School, UK</td>
</tr>
<tr>
<td>15.20 – 15.30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Radiotherapy and radiobiology

**Room 11** Hosted by Adrian Crellin, St. James’s Institute of Oncology & Vice President, The Royal College of Radiologists, UK

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.10</td>
<td>In vivo imaging of DNA damage response during tumourigenesis</td>
<td>Bart Cornelissen, University of Oxford, UK</td>
</tr>
<tr>
<td>14.20 – 14.30</td>
<td>Targeting radiation-resistant hypoxic tumour cells through ATR inhibition</td>
<td>Ester Hammond, Gray Institute for Radiation Oncology and Biology, University of Oxford, UK</td>
</tr>
<tr>
<td>14.30 – 14.40</td>
<td>AEG-1 expression is related to radiation response in rectal cancer patients from a clinical trial of preoperative radiotherapy and in cancer cell lines</td>
<td>Sebastian Gnosa, University of Linköping, Sweden</td>
</tr>
<tr>
<td>14.40 – 14.50</td>
<td>$^{111}$In-bnDTPA-bevacizumab for imaging VEGF and assessing response to rapamycin therapy</td>
<td>Neel Patel, University of Oxford, UK</td>
</tr>
</tbody>
</table>
14.50 – 15.00  Quality of life (QOL) and updated survival and safety data of radium-223 chloride (Ra223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 ALSYMPCA study
Christopher Parker, The Royal Marsden NHS Foundation Trust, London, UK

15.00 – 15.10  p16INK4A predicts outcome following chemo-radiotherapy in squamous cell cancers of the anus
Duncan Gilbert, Royal Sussex County Hospital & Brighton and Sussex Medical School, UK

15.10 – 15.20  Liver stereotactic body radiation therapy (SBRT) for treatment refractory metastatic liver disease
Katharine Aitken, The Royal Marsden NHS Foundation Trust, London, UK

15.20 – 15.30  Discussion

The cancer cell and model systems II
Hall 1A  Hosted by Caroline Dive, Paterson Institute for Cancer Research, Manchester, UK

14.00 – 14.15  BACR Frank Rose Award: Metastasis driven by the tumour microenvironment
Janine T. Erler, University of Copenhagen, Denmark

14.15 – 14.30  BACR Translational Research Award: Characterisation of expressed fusion genes in micropapillary carcinomas of the breast
Rachael Natrajan, The Institute of Cancer Research, London, UK

14.30 – 14.40  RASSF1A loss deregulates hippo pathway signalling in tumourigenesis
Angelos Papaspyropoulos, University of Oxford, UK

14.40 – 14.50  Mechanisms of DNA replication initiation
Thomas Deegan, Cancer Research UK, Clare Hall Laboratories, Potters Bar, UK

14.50 – 15.00  Contrasting effects of sunitinib within in vivo models of metastasis
Andrew Reynolds, The Institute of Cancer Research, London, UK

15.00 – 15.10  The receptor tyrosine kinase EpHA2 is a poor prognostic marker and a novel target in Kras mutant colorectal cancer
Philip Dunne, Queen’s University Belfast, UK

15.10 – 15.20  Induced pluripotent stem cell (iPSC) reprogramming of the elderly human prostate into a primitive embryonic stem cell state - a model for prostatic development and carcinogenesis
Deepali Pal, Northern Institute for Cancer Research, Newcastle University, UK

15.20 – 15.30  Discussion
Workshops TUESDAY

Educational Workshops

Translation of radiation biology into meaningful clinical trials: All aboard!
Hosted by Ricky Sharma, University of Oxford, UK
08.00 – 08.45, Room 11

Speakers:
Introduction and overview
Ricky Sharma, University of Oxford, UK

PARP inhibition as an example of translation from preclinical models to clinical trials
Anthony Chalmers, University of Glasgow, UK

Clinical trials with radiotherapy: Keys to success
David Sebag-Montefiore, Leeds Teaching Hospitals NHS Trust, UK

Discussion
Ricky Sharma, University of Oxford, UK

Cutting edge translational research in head and neck cancer
Hosted by Hisham Mehanna, Institute of Head and Neck Studies and Education, Coventry, UK
11.00 – 15.00, Room 4

Objectives of the workshop:

1. Provide an update on cutting edge translational research in head and neck cancer (HNC) including deep sequencing, miRNA, mining public data bases.
2. Provide an update on developments in the field of HPV in HNC.
3. Provide a forum for young researchers to present their translational research in HNC.
4. Provide a platform for the development of collaborations between researchers and research groups in translational medicine in HNC.

Target audience:

1. Clinicians and researchers wishing to be updated on developments in translational research.
2. PhD and MSc students wishing to present their work in translational research in head and neck cancer.

Speakers:

Introduction: Working with the Head and Neck CSG and the Biomarker and Imaging CSG
Robert Brown, Imperial College London, UK and Hisham Mehanna, InHANSE University Hospitals Coventry and Warwickshire, Coventry, UK

Designing a translational project in cancer - what are the challenges and pitfalls? (Funding sources, the biomarker roadmap, reporting and more)
Andrew Hall, Newcastle Cancer Centre, UK
Keynote Lecture: The challenges of working at the frontier - deep sequencing in head and neck cancer

Jeff Myers, MD Anderson Cancer Center, Houston, USA

Recent developments in our understanding of HPV - head and neck cancer, epidemiology, mechanisms, treatments, vaccination...

Ned Powell, Cardiff University, UK

New biomarkers in head and neck cancer - methylation and miRNA

Mahyash Tavassoli, King’s College London, UK

Harnessing the power of bioinformatics: Making use of high volume data analyses and mining public databases

Edward Curry, Imperial College London, UK

Summation

Gareth Thomas, University of Southampton, UK

Closed session (by invitation)

Delivering collaborations and high quality translational research in head and neck cancer - can we do it better?

Moderator: Richard Shaw, University of Liverpool, UK

Commercial Workshop

Headlines of International Conferences in 2012
Sponsored by Roche Products Limited

13.00 – 14.00, Room 11

What have been the latest developments in cancer research and treatment? Taking the data from past congresses, the Roche-sponsored symposium will present an independent view of the headline data from this year’s key congresses.

Roche Products Limited welcomes all NCRI delegates to attend this Roche-sponsored symposium and hear from a clinician’s perspective how the highlights of congresses such as the American Society of Clinical Oncology Annual Meeting could impact on patient care in the UK.

This symposium is sponsored by Roche Products Limited – with no editorial control on content

Afternoon Workshops

Improving the management of cerebral metastatic disease
Hosted by NCRI Brain Tumour Clinical Studies Group, UK

14.00 – 15.30, Room 12

The oncology team responsible for the primary cancer generally manages cerebral metastatic disease. Recent data suggests that management can be refined by more rigorous patient stratification and the application of a multimodal approach to treatment.

The purpose of this workshop will be to address the following questions:

1. Can we develop a national stratified approach to the management of cerebral metastatic cancer?
2. Is there a role for greater involvement of neuro-oncologists?

The workshop is aimed at oncologists, surgeons, nurses and pathologists involved in the management of patients with cerebral metastases. The overall aim is simple: “Can we do what we do better?”

References


Transforming oncology research: New models for novel therapeutic approaches

Hosted by French National Cancer Institute (INCa), France
14.00 – 15.30, Room 3B

The outstanding challenge in cancer research is to rapidly and cost-effectively translate the growing knowledge and developments in tumour biology and technology into new therapeutics.

The traditional preclinical models lack predictability for the clinical outcomes due to major differences in tumour biology, pathophysiology and tumour microenvironment. Similarly, small animals are insufficient for the development of new technologies for early detection of cancers.

Cancer is the commonest cause of death in dogs for which the main modalities of treatment are the same as in humans. Recently, comparative oncology studies (genetic, biological, clinical characterisation…) have revealed important similarities between canine tumours and corresponding human diseases and comparable responses to radiotherapy and systemic treatments. Taken together, canine spontaneous tumours have emerged as a promising model to bridge the gap between existing models and the clinic.

The support and the development of alternative preclinical models that better predict the clinical response to anti-cancer treatments was earmarked as a priority area in the 2009-2013 French Cancer Plan. Dedicated support to research projects involving vets, biologists and clinical teams has been provided for the last two years by Inserm and the French National Cancer Institute (INCa).

Since no European country has sufficient capacity to meet this objective alone, gathering resources at a European and international level is now necessary to pool skills and resources for joint research programs and collaboration. To this purpose, a European network, regrouping experts in basic and applied comparative oncology, is being set up to enlarge complementarities between human and veterinary research to develop new treatments, improving assessment and deciphering the molecular mechanisms underlying certain tumour types. The session hosted by INCa presents this network and the research objectives that would strengthen the link between existing preclinical models and human medicine by integrating naturally occurring canine cancers into cutting-edge translational cancer research.

Speakers:

Introduction
Robin Fahraeus, INSERM, Paris, France

Tumour biology and target identification
Ted Hupp, Edinburgh University, UK

Application of genomics technology in a consortium
Catherine Andre, CNRS, University of Rennes, France

Imaging, nanotechnologies and engineering applications
Annemarie Kristensen, The University of Copenhagen, Denmark
Nanoparticle based imaging of cells and tissue
Duncan Graham, The University of Strathclyde, UK

Transforming clinical practice through a clinical network
David Argyle, The University of Edinburgh, UK
Programme at a Glance WEDNESDAY

Prize Winners Announcement
09.00 – 09.10  Prize Winners Announcement
Hall 1A

Plenary Lecture
Chaired by Katherine Vallis, Gray Institute for Radiation Oncology and Biology, Oxford, UK
09.10 – 09.50  Personalised genomic approaches and pathway identification for individualised prostate cancer therapy
Hall 1A
Robert G. Bristow, Ontario Cancer Institute/Princess Margaret Cancer Center & University of Toronto, Canada

Parallel Sessions
10.00 – 11.30  Assessing the economics of cancer care
Hall 1B  Hosted by Peter Smith, Imperial College Business School & Centre for Health Policy, London, UK
10.00 – 11.30  Can this patient die comfortably at home?: Knowing the risks and what helps
Room 12  Hosted by Barbara Gomes, Cicely Saunders Institute, King’s College London, UK
10.00 – 11.30  Clinical implications of clonal evolution and personalising therapy
Room 3A  Hosted by Faith Davies, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK
10.00 – 11.30  Expanding the druggable genome
Room 3B  Hosted by Martin Drysdale, The Beatson Institute for Cancer Research, Glasgow, UK
10.00 – 11.30  Prostate cancer: The androgen receptor takes centre stage
Room 4  Hosted by Malcolm Mason, Cardiff University, UK
10.00 – 11.30  Role of aspirin and other NSAIDs in cancer prevention
Hall 1A  Hosted by Jack Cuzick, Wolfson Institute of Preventative Medicine, London, UK
10.00 – 11.30  Tumour angiogenesis
Room 11  Hosted by Kairbaan Hodivala-Dilke, Centre for Tumour Biology, Barts Cancer Institute, London, UK

Refreshment Break
11.30 – 11.50  Refreshment break
Registration area & Galleria
Plenary Lecture
Chaired by Nic Jones, Manchester Cancer Research Centre and Cancer Research UK

11.50 – 12.30  Functional genomics, experimental models and cancer
  Hall 1A  William Hahn, Dana-Farber Cancer Institute, Boston, USA

Lunch

12.40 – 13.30  Lunch (available to take away)

Satellite symposia

13.30 – 16.30  Satellite symposia
Parallel Sessions WEDNESDAY

KEY TO THEMES:
- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

Assessing the economics of cancer care

Hall 1B  Hosted by Peter Smith, Imperial College Business School & Centre for Health Policy, London, UK
10.00 – 10.10  Introduction
   Peter Smith, Imperial College Business School & Centre for Health Policy, London, UK
10.10 – 10.15  The economics of survivorship
   Siobhan McClelland, Macmillan Cancer Support, London, UK
10.15 – 10.40  Value of information analysis within a stakeholder-driven research prioritisation process: An application in cancer genomics
   Scott Ramsey, Fred Hutchinson Cancer Research Center & University of Washington, Seattle, USA
10.40 – 11.05  The economic burden of cancer across the European Union
   Jose Leal, University of Oxford, UK
11.05 – 11.30  Cancer services in England: Providing value for money?
   Peter Smith, Imperial College Business School & Centre for Health Policy, London, UK

Can this patient die comfortably at home?: Knowing the risks and what helps

Room 12  Hosted by Barbara Gomes, Cicely Saunders Institute, King’s College London, UK
10.00 – 10.15  Introduction
   Barbara Gomes, Cicely Saunders Institute, King’s College London, UK
10.15 – 10.40  Cross-national variations in place of death of cancer patients
   Joachim Cohen, Vrije Universiteit Brussel, Brussels, Belgium
10.40 – 11.05  Improving care delivery and personality care: Integrating ASyMS to cancer care
   Nora Kearney, University of Dundee, UK
11.05 – 11.30  Promoting quality of life and care of advanced cancer patients: What factors matter most?
   Holly Prigerson, Dana-Farber Cancer Institute, Boston, USA
Clinical implications of clonal evolution and personalising therapy
Room 3A Hosted by Faith Davies, The Institute of Cancer Research, London, UK
10.00 – 10.15 Introduction
Faith Davies, The Institute of Cancer Research & The Royal Marsden
NHS Foundation Trust, London, UK
10.15 – 10.40 Risk-driven therapy in acute myeloid leukaemia
Alan Burnett, Cardiff University, UK
10.40 – 11.05 Founding clones and evolving subclones: Insights in acute myeloid
leukaemia from next-generation sequencing
John Welch, Washington University, St. Louis, USA
11.05 – 11.30 The clinical impact of advances in the genetic understanding of cancer
Gareth Morgan, The Institute of Cancer Research, London, UK

Expanding the druggable genome
Room 3B Hosted by Martin Drysdale, The Beatson Institute for Cancer
Research, Glasgow, UK
10.00 – 10.15 Introduction
Martin Drysdale, The Beatson Institute for Cancer Research, Glasgow, UK
10.15 – 10.40 Enriching chemical space to drug undruggable targets
David Spring, University of Cambridge, UK
10.40 – 11.05 Drugging the undruggable: Small-molecule inhibition of Ras oncoprotein I
Guowei Fang, Genentech/Roche, California, USA
11.05 – 11.30 Bromodomain inhibitors extend the druggable genome: From
phenotypic screening to first time in man
Chun-wa Chung, GlaxoSmithKline, Stevenage, UK

Prostate cancer: The androgen receptor takes centre stage
Room 4 Hosted by Malcolm Mason, Cardiff University, UK
10.00 – 10.15 Introduction
Malcolm Mason, Cardiff University, UK
10.15 – 10.40 Androgen receptor co-regulatory proteins as alternative therapeutic
targets in prostate cancer
Craig Robson, Northern Institute for Cancer Research, Newcastle
University, UK
10.40 – 11.05 Biological insights arising from the identification of genes and
pathways that are regulated by the androgen receptor
Ian Mills, University of Oslo, Norway & Cancer Research UK Cambridge
Research Institute, UK
11.05 – 11.30 Targeting the androgen receptor in castration-resistant prostate cancer
Gerhardt Attard, The Institute of Cancer Research, London, UK

Role of aspirin and other NSAIDs in cancer prevention
Hall 1A Hosted by Jack Cuzick, Wolfson Institute of Preventative Medicine,
London, UK
Parallel Sessions WEDNESDAY 7

10.00 – 10.05
Introduction
Jack Cuzick, Wolfson Institute of Preventative Medicine, London, UK

10.05 – 10.30
Aspirin and cancer: Evidence from randomised trials
Nancy Cook, Brigham and Women’s Hospital & Harvard Medical School, Boston, USA

10.30 – 10.55
Aspirin and cancer risk: A meta-analysis to 2011
Carlo LaVecchia, Istituto di Ricerche Farmacologiche Mario Negri & University of Milan, Italy

10.55 – 11.20
Cancer prevention with aspirin: Randomised trial evidence
John Burn, Newcastle University, UK

11.20 – 11.30
Discussion

Tumour angiogenesis

Room 11 Hosted by Kairbaan Hodivala-Dilke, Centre for Tumour Biology, Barts Cancer Institute, London, UK

10.00 – 10.15
Introduction
Kairbaan Hodivala-Dilke, Centre for Tumour Biology, Barts Cancer Institute, London, UK

10.15 – 10.40
Histidine-rich glycoprotein in tumour vessel normalisation and anti-tumour immune responsiveness
Lena Claesson-Welsh, Uppsala University, Sweden

10.40 – 11.05
Time to branch? Endothelial cell dynamics regulating vascular patterning
Holger Gerhardt, Cancer Research UK London Research Institute, UK

11.05 – 11.30
Tumour invasion and metastasis: Reduction by concurrent inhibition of c-MET and VEGF signalling
Donald McDonald, University of California, San Francisco, USA